Kolf 2.1 J (FUS R495X SNV/SNV)
WTSIi018-B-25
General
Cell Line |
|
| hPSCreg name | WTSIi018-B-25 |
| Cite as: | WTSIi018-B-25 |
| Alternative name(s) |
Kolf 2.1 J (FUS R495X SNV/SNV)
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
WTSIi018-B-24 (Kolf 2.1 J (FUS R495X WT/SNV)) WTSIi018-B-26 (Kolf 2.1 J (FUS R521H WT/SNV)) WTSIi018-B-27 (Kolf 2.1 J (FUS R521H SNV/SNV)) WTSIi018-B (HPSI0114i-kolf_2) UCSFi001-A-74 (FUS-P525L HET 2D1) UCSFi001-A-75 (FUS-P525L HOM 2D2) CBIGi001-A-37 (IPSC0109, FUS-H517Q/AIW002-02) CBIGi001-A-38 (IPSC0110, FUS-KO/AIW002-02) UCSFi001-A-72 (FUS-R521G HET 2B10, LSUHSi004-A-72) UCSFi001-A-73 (FUS-R521G HOM 1D9) WTSIi018-B-18 (Kolf 2.1 J (TARDBP M337V WT/SNV)) WTSIi018-B-21 (Kolf 2.1 J (TARDBP M337V SNV/SNV)) WTSIi018-B-22 (Kolf 2.1 J (TARDBP Q331K WT/SNV)) WTSIi018-B-23 (Kolf 2.1 J (TARDBP Q331K SNV/SNV)) WTSIi018-B-28 (DU411) WTSIi018-B-29 (DU414) WTSIi018-B-30 (DU434) WTSIi018-B-12 (KOLF2.1J) WTSIi018-B-1 (HPSI0114i-kolf_2-C1) WTSIi018-A (HPSI0114i-kolf_3) CBIGi022-A-1 (SOD1 I114T correction (CBIGi022-A), IPSC0029) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi001-A-19 (IPSC0084, SOD1 G93A/AIW002-02) CBIGi001-A-22 (TARDBP-A382T/AIW002-02, IPSC0089) CBIGi001-A-23 (TARDBP-G348C/AIW002-02, IPSC0090) CBIGi001-A-31 (IPSC0103, C9ORF72-KO/AIW002-02) UQi001-A-1 (C11-TDP43-A382T) CBIGi001-A-7 (IPSC0068, OPTN-KO/AIW002-02) CBIGi001-A-11 (IPSC0075, PRKN Y143D/AIW002-02) CBIGi001-A-12 (PRKN-V393D/AIW002-02, IPSC0076) CBIGi001-A-13 (IPSC0078, SCARB2-KO/AIW002-02) CBIGi001-A-14 (IPSC0079, SH3GL2-KO/AIW002-02) CBIGi001-A-15 (SNCA A30P/AIW002-02, IPSC0080) CBIGi001-A-16 (IPSC0081, SNCA A53T/AIW002-02) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) CBIGi001-A-17 (IPSC0082, SNCA E46K/AIW002-02) BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) CBIGi001-A-18 (IPSC0083, SNCA-KO/AIW002-02) CBIGi001-A-21 (IPSC0086, SMPD-KO/AIW002-02) BIONi010-C-25 (BIONi010-C heterozygous TREM2 KO) CBIGi001-A-24 (TMEM163-KO/AIW002-02, IPSC0096) CBIGi001-A-25 (IPSC0097, TMEM175-KO/AIW002-02) BIONi010-C-70 (BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation) BIONi010-C-71 (BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation) |
| Last update | 6th March 2024 |
| User feedback | |
Provider |
|
| Generator |
Max Delbrück Center Berlin Buch (MDC)
Contact:
Jackson Laboratories (JAX) |
| Owner | Jackson Laboratories (JAX) |
| Distributors | |
| Derivation country | United Kingdom |
External Databases |
|
| BioSamples | SAMEA115377803 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | White - White British |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA2398402 |
| HipSci | HPSI-kolf |
Ethics
Also have a look at the ethics information for the parental line
WTSIi018-B
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
WTSIi018-B.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
Other medium:
Base medium: StemFlex
Main protein source: Serum concentration: % |
Characterisation
No characterisation data could be found for this subclone. Please open parental cell line WTSIi018-B .Genotyping
Karyotyping (Cell Line) |
|
Other Genotyping (Cell Line) |
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.